Abstract
Tumor mutational burden-high (TMB-H) is the indication biomarker for pan-cancer immunotherapy approved by FDA. However, the understanding of the molecular and clinical characteristics of TMB-H lung cancer still limited, especially in Chinese patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
